MP36-16 RENAL FUNCTION IMPROVES UNDER LONG-TERM TESTOSTERONE THERAPY IN MEN WITH HYPOGONADISM AND TYPE 2 DIABETES: REAL-WORLD EVIDENCE FROM A UROLOGICAL REGISTRY

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy II (MP36)1 Sep 2021MP36-16 RENAL FUNCTION IMPROVES UNDER LONG-TERM TESTOSTERONE THERAPY IN MEN WITH HYPOGONADISM AND TYPE 2 DIABETES: REAL-WORLD EVIDENCE FROM A UROLOGICAL REGISTRY Karim Sultan Haider, Ahmad Haider, Gheorghe Doror, and Abdulmaged Traish Karim Sultan HaiderKarim Sultan Haider More articles by this author , Ahmad HaiderAhmad Haider More articles by this author , Gheorghe DororGheorghe Doror More articles by this author , and Abdulmaged TraishAbdulmaged Traish More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002045.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Hypogonadism is highly prevalent in patients with type 2 diabetes mellitus (T2DM). Diabetic nephropathy is one of the common diabetic complications. We investigated effects of testosterone therapy on renal parameters and renal function in men with hypogonadism and T2DM. METHODS: In a registry of 865 men with hypogonadism, 361 men (41.7%) had T2DM. 183 received TU 1000 mg every 12 weeks (T-group), 178 opted against treatment and served as controls (CTRL). Changes over time between groups were compared and adjusted for age, weight, waist circumference, fasting glucose, blood pressure, lipids and quality of life to account for baseline differences between the groups.Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) formula. RESULTS: Mean age at baseline: 60.7±5.5 years (T-group) and 63.0±4.9 (CTRL) (p<0.0001). Mean (median) follow-up: T-group 8.2±3.2 (8), CTRL 9.2±2.8 (10) years. Trough levels of total testosterone (nmol/L) prior to the next injection increased by 2.6±0.1 at 12 years in the T-group and decreased by 0.8±0.1 in CTRL, estimated adjusted difference between groups at 12 years: 3.4 [95% CI: 3.2; -3.6] (p<0.0001 for all). Creatinine (mg/dL) decreased by 0.16±0.03 at 12 years in the T-group and increased by 0.33±0.03 in CTRL, estimated adjusted difference between groups at 12 years: -0.57 [95% CI: -0.68; -0.46] (p<0.0001 for all). γGT (U/L) decreased by 22.0±1.2 at 12 years in the T-group and increased by 21.0±1.2 in CTRL, estimated adjusted difference between groups at 12 years: -43.0 [95% CI: -46.9;-39.1] (p<0.0001 for all). eGFR (mL/min/1.73 m2) increased by 15.1±5.6 (T-group), reaching a peak in year 9. eGFR decreased progressively by 22.9±5.6 (CTRL), estimated adjusted difference between groups at year 12: 38.0 [95% CI: 20.4;55.7] (p<0.0001 for all). Systolic blood pressure (mmHg) decreased in the T-group by 33.1±1.2 and increased in CTRL by 18.3±1.2, difference between groups: -51.5 [95% CI: -55.4;-47.6] (p<0.0001 for all).Diastolic blood pressure (mmHg) decreased by 20.3±0.9 (T-group) and increased by 12.5±0.9 (CTRL), difference between groups: -32.8 [95% CI: -35.7;-29.9] (p<0.0001 for all). 15 deaths (8.3%) occurred in the T-group, 61 deaths (34.3%) in CTRL. Diabetic nephropathy occurred in 0.01% in the T-group and in 2.8% in CTRL (p<0.05). CONCLUSIONS: Long-term testosterone therapy in men with hypogonadism and T2DM improves renal function demonstrated by eGFR. Source of Funding: Data entry and statistical analysis was compensated by Bayer AG © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e642-e642 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Karim Sultan Haider More articles by this author Ahmad Haider More articles by this author Gheorghe Doror More articles by this author Abdulmaged Traish More articles by this author Expand All Advertisement Loading ...